TabletsClinical Overview
Hydrochlorothiazide Tablets 25 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with a full glass of water at scheduled times as prescribed. Maintain regular blood pressure and cardiac monitoring; do not discontinue abruptly.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, headache, mild fatigue, gastrointestinal distress, postural hypotension. Rare/Severe: Severe hypotension, electrolyte imbalances, heart block, and hypersensitivity reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Prescription cardiovascular medication. Do not discontinue without medical consultation, as abrupt cessation may cause rebound hypertension or cardiac events. Regularly monitor blood pressure and organ function.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Losartan Potassium 50mg + Hydrochlorothiazide 12.5mg Tabelts
Losartan Potassium and Hydrochlorothiazide combines a selective AT1 receptor blocker with a thiazide diuretic on the WHO Model List of Essential Medicines. Losartan blocks angiotensin II-induced vasoconstriction and uniquely possesses intrinsic uricosuric properties that increase uric acid excretion, offsetting the hyperuricemic tendency of hydrochlorothiazide, while hydrochlorothiazide reduces extracellular fluid volume. Indicated for the treatment of hypertension not adequately controlled on monotherapy and for reducing stroke risk in hypertensive patients with left ventricular hypertrophy.
Telmisartan 40mg + Hydrochlorothiazide 12.5mg Tablets
Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.
Ramipril 5mg + Hydrochlorothiazide 12.5mg Tablets
Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.
Olmesartan Medoxomil 40mg + Hydrochlorothiazide 12.5mg Tablets
Olmesartan Medoxomil is a potent, orally active prodrug that is rapidly de-esterified during absorption to olmesartan, a selective and insurmountable competitive antagonist at the angiotensin II AT1 receptor. It produces profound, prolonged reductions in systemic vascular resistance and blood pressure throughout the 24-hour dosing interval. Indicated for the treatment of essential hypertension alone or in combination with other antihypertensive agents (amlodipine, cilnidipine, chlorthalidone, hydrochlorothiazide).